Key Highlights

  • Jupiter Neurosciences' board approved a 1-for-75 reverse stock split, legally effective at 4:01 p.m. Eastern Time on August 6, 2026.
  • The split will reduce outstanding shares from approximately 57.76 million as of August 4, 2026, to approximately 770,081 shares.
  • Shares will begin trading on a split-adjusted basis under a new CUSIP number on August 7, 2026, while retaining the current ticker symbol.
  • The reverse split is intended to help the company regain compliance with Nasdaq's minimum bid price requirement for continued listing on the Nasdaq Capital Market.

Board Approves Reverse Split to Address Nasdaq Compliance

Jupiter Neurosciences (NASDAQ:JUNS) announced that its board of directors approved a 1-for-75 reverse stock split of the company's common stock, following stockholder approval at the company's annual meeting held on July 22, 2026. The reverse split will legally take effect at 4:01 p.m. Eastern Time on August 6, 2026, converting every 75 shares of existing common stock into one share. No fractional shares will be issued; stockholders who would otherwise hold a fractional share will instead receive a cash payment based on the closing price of the stock on the trading day immediately before the split takes effect.

Share Count to Fall Sharply as Trading Resumes Under New CUSIP

The reverse split will reduce Jupiter Neurosciences' outstanding shares from approximately 57.76 million as of August 4, 2026, to approximately 770,081 shares, while the total number of authorized shares remains unchanged. Proportional adjustments will also apply to the exercise and conversion prices of the company's outstanding stock options and convertible securities, as well as to shares issued and issuable under its stock incentive plans. The company's common stock will begin trading on a split-adjusted basis on the Nasdaq Capital Market on August 7, 2026, under a new CUSIP number while retaining its existing ticker symbol. Stockholders holding shares electronically or through a bank or broker will have their positions automatically adjusted without requiring any action, while holders of physical stock certificates will receive exchange instructions from the company's transfer agent.

Split Aims to Restore Compliance With Listing Standards

The reverse split is intended to increase Jupiter Neurosciences' per-share trading price to help the company regain compliance with Nasdaq's minimum bid price requirement for continued listing on the Nasdaq Capital Market. Shares traded lower following the announcement, a common market reaction to reverse split news as investors weigh the change in share structure. The company's lead pipeline asset, JOTROL, an enhanced-bioavailability resveratrol formulation, remains in a Phase IIa clinical trial for Parkinson's disease, and continued clinical progress alongside the completed reverse split may factor into how the stock performs once compliance is addressed.

Conclusion

Jupiter Neurosciences' 1-for-75 reverse stock split represents a structural step aimed at preserving the company's Nasdaq listing rather than a change to its underlying business or clinical programs. With outstanding shares reduced to roughly 770,081, the company will need to sustain compliance with Nasdaq's minimum bid price requirement over the required period following the split's effective date. Attention is likely to remain on the company's clinical pipeline, including its Phase IIa Parkinson's disease trial, as a longer-term driver of its trading performance.